Biogen’s Aducanumab: One Positive Phase III Trial Is Good Enough For Demonstrating Efficacy, US FDA Says

 
• By Sue Sutter
New life idea concept with seedling growing sprout (tree)
US FDA believes the Phase III EMERGE trial can stand on its own as pivotal efficacy evidence for aducanumab. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers